Leading with Light: MUSE Microscopy Illuminates the Next Era of Oncology at ASCO

/EIN News/ -- IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, (the “Company”, “we”, “our”) a leader in slide-free, tissue-to-digital™ pathology solutions, is excited to announce its participation in the upcoming American Society of Clinical Oncology (ASCO) 2025, taking place from May 30 – June 03 in Chicago, IL. Following our successful introduction of SmartPath MUSE Technology™ (SmartPath), the first tissue-to-digital imager utilizing Microscopy with Ultraviolet Surface Excitation (MUSE) at the recent USCAP25 in Boston, we are eager to demonstrate our innovative technology at ASCO.   

ASCO 2025 attracts thousands of industry leaders worldwide, providing a platform for sharing and exploring the latest advancements in cancer care.  

"MUSE Microscopy’s presence at ASCO underscores our commitment to redefining oncology diagnostics at the cellular level. As the industry converges to advance precision medicine, MUSE stands as the natural evolution—where speed, clarity, and digital intelligence can replace glass, guesswork, and delay", said Matthew Nuñez, CEO, MUSE Microscopy. 

We invite attendees to visit us at booth 10042 or schedule a meeting with one of our experts at ASCO to learn how our SmartPath Imager is set to revolutionize the pathology landscape. SmartPath is designed to streamline workflows and improve the experiences of both patients and physicians, enabling quicker and more informed decision-making in digital pathology. 

“USCAP25 was a tremendous success for us, and we appreciate everyone who visited our booth,” added Nuñez. “We are committed to eliminating cumbersome manual processes and propelling the pathology field into a fully digital future.”  

Looking ahead, MUSE Microscopy is dedicated to making SmartPath* widely available for digital pathology use, and we have an exciting year planned. For more information, please visit us at Muse Microscopy | Tissue-to-Digital Pathology or contact us at 866.299.8998. *Pending FDA approval. 

About MUSE Microscopy, Inc.  
MUSE Microscopy, Inc. is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We are developing a MUSE-enabled imaging system for diagnostic assistance in pathology, cytology, and research applications. SmartPath MUSE Technology™ (SmartPath), is intended to be a slide-free tissue-to-digital imaging platform that aims to revolutionize digital pathology by eliminating the need for traditional slide-based histology. Our goal is to offer a first-to-market, non-destructive imaging solution.  

To learn more, you can visit their website at https://musemicroscopy.com/ or find them on social media platforms such as X, Facebook, and LinkedIn.

Limits on Accuracy 
This press release is intended to provide information about MUSE Microscopy, Inc.’s research and potential products. Information is believed to be accurate at the time it is created. However, like any printed material, information may become outdated over time. Information may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice. There may also be improvements or changes in the products and services described in this press release at any time without notice. It is important that you rely on the advice of an appropriate professional. Nothing contained in any presentation is to be construed as medical, legal, investment, financial, or other advice. This information is not intended to be a substitute for such advice. MUSE Microscopy, Inc. does not endorse any specific techniques or methods of treatment. Individuals are advised to consult their health care professionals for full information about the potential adverse reactions from use of the medical technologies discussed in this press release. We will use reasonable efforts to include accurate and up-to-date information on the website, but MUSE Microscopy, Inc. makes no warranties or representations regarding its accuracy.  

Forward-Looking Statements  
Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “termed,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. 

Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. 

CONTACT: 
Matthew Nuñez 
Tel: 949.813.6121  
mnunez@musemicroscopy.com 

 Source: MUSE Microscopy, Inc.